| Aug 14 |
Zomedica Corp. (ZOM) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
Zomedica reports Q2 results
|
| Aug 14 |
Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
|
| Aug 14 |
Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
|
| Aug 1 |
Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
|
| Jul 17 |
The United States Eventing Association Names Zomedica’s PulseVet(R) as the Official Shock Wave of the USEA
|
| Jul 9 |
Zomedica Expands Global Reach Through Strategic Alliance with Leader Healthcare Group for Sales Expansion in Key International Markets
|
| Jul 1 |
US Equestrian Names Zomedica’s PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians
|
| Jun 27 |
Zomedica Expands TRUFORMA Addressable Market with Launch of Equine Cortisol Assay for the Platform
|
| Jun 25 |
Zomedica Expands Market Opportunity for the TRUFORMA Point-of-Care Diagnostic Platform by Securing CE Mark
|
